Drug Trial Radar · NCT03603106
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions
Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
142
Actual
Start
Nov 25, 2013
Primary completion
Apr 17, 2015
Study completion Apr 17, 2015
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the safety (clinical and biological) and pharmacokinetics (plasma and urine) profile of P03277 following single administration at ascending dose levels in healthy subjects.
Conditions
- Healthy Volunteers
- Brain Lesion
Interventions
P03277Drug
Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.
PlaceboDrug
Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Parameter CmaxTime frame: From baseline (30 minutes before injection) to 24 hours post-injection
- PK Parameter T1/2Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
- PK Parameter ClTime frame: From baseline (30 minutes before injection) to 24 hours post-injection
- PK Parameter VdTime frame: From baseline (30 minutes before injection) to 24 hours post-injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology unit, SGS Life Science Services
Antwerp, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.